Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting No phase listed Observational

FLASH Biomarker Study

ClinicalTrials.gov ID: NCT07942077

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07942077. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Biomarker Characterization in Patients Undergoing Ultra-High Dose Rate (ConformalFLASH®) on the C-FLASH-01 Trial

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a single-center, non-interventional biospecimen collection protocol that accompanies C-FLASH-01 (Protocol IBA-04-UP, IDE G260113), a pilot trial of ultra-high dose rate proton reirradiation (ConformalFLASH) for head and neck cancer. Blood and saliva will be collected from up to 10 participants enrolled on the C-FLASH-01 trial at three time points: 1) within 4 weeks before the start of radiotherapy, 2) within 3 days of the last day of radiotherapy, and 3) within 4 months after completion of radiotherapy.

Study identification

NCT ID
NCT07942077
Recruitment status
Not yet recruiting
Study type
Observational
Phase
Not listed
Enrollment
10 participants

Conditions and interventions

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 1, 2026 (Estimated)
Primary completion
Nov 1, 2029 (Estimated)
Completion
Nov 1, 2029 (Estimated)
Last update posted
Nov 17, 2026

2026 – 2029

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Perelman Center for Advanced Medicine, Department of Radiation Oncology Philadelphia Pennsylvania 19104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07942077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.